G1 Therapeutics Phase 3 Trial Update: Market Response
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
- Latest
- Trending
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
A company has launched various objects into orbit for advertising purposes, showcasing its investment in research and development. This innovative ...
Shares of banks and other financial institutions have risen as investors await key inflation data. The possibility of rate cuts ...
Federal Realty Investment Trust reports a decrease in net income for 2023, but shows growth in funds from operations and ...
Diamondback Energy and Endeavor Energy's merger has created a $50 billion oil-and-gas powerhouse, driven by surging oil prices and competition ...
Apps are offering solutions for dating situations gone wrong, providing features such as fake calls and discreet messaging to ensure ...
Financial advisors play a crucial role in estate planning, guiding individuals through complexities to ensure assets are distributed as desired. ...
AssetMark Financial Holdings, Inc. reports a 14.5% YoY increase in platform assets, reaching $109.7 billion, along with a 24.5% rise ...
Activist investor Carl Icahn has disclosed a 9.9% stake in JetBlue Airways, stating it is undervalued. He is engaging in ...
FCC Commissioner Brendan Carr has urged an investigation into Apple's shutdown of the Beeper Mini, citing concerns over compliance with ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.